In 2020, the Chinese orthobiologics market size was valued at $460.7 million, with over 424,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 6% to reach $690.8 million in 2026. Throughout this medical market research, we analyzed 28 orthobiologics companies across China
In 2020, the Indian orthobiologics market size was valued at $76.2 million, with over 520,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 12.4% to reach $172.3 million in 2026. Throughout this medical market research, we analyzed 23 orthobiologics companies across India
In 2020, the Australian orthobiologics market size was valued at $63.8 million, with over 29,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 4.9% to reach $89.4 million in 2026. Throughout this medical market research, we analyzed 48 orthobiologics companies across Australia
The total European orthobiologics market is growing at a rate of 1.6%, which will take the 2018 market value of €521.2 million up to €582.3 million by 2025. Constraints on reimbursements will continue to limit the European orthobiologics market. Presently, only a few premium products under the umbrella of pharmaceuticals are reimbursed by the government
The total US orthobiologics market is growing at a rate of 4.9%, which will take the 2018 market value of $3.6 billion up to $5 billion by 2025. A particular trend in the U.S. orthobiologics market is competitors that are seeking to penetrate high growth segments outside their traditional space by distributing existing products manufactured
Industry Trends A particular trend in the U.S. orthobiologics market is competitors that are seeking to penetrate high growth segments outside their traditional space by distributing existing products manufactured by other companies, rather than creating their own. This often involves partnering with a company by taking on the costs associated with regulation and market approval,
Bone morphogenetic proteins (BMPs) are growth factors that induce the formation of bone after a fracture. In nature, these proteins have a critical role during embryonic development in the formation of the skeleton. There are twenty different BMPs that have been discovered thus far, of which only two, BMP-2 and BMP-7, have been commercialized as bone graft substitutes for use in specific orthopedic procedures. The commercial versions of these products are produced by recombinant genetic engineering, which results in a recombinant human protein. The recombinant human BMP-2 (rhBMP-2) is marketed as a commercial product by Medtronic, Inc. and is called Infuse® (InductOS® in Europe), while BMP-7 has been commercialized by Stryker Inc. and is sold to Olympus under the name of OP-1®. Both molecules mediate the process of osteoblast differentiation. BMP-2 is capable of stimulating immature mesenchymal cells to form into bone, while BMP-7 has been shown to be capable of stimulating cartilage growth.
Growth factors are a group of small, soluble proteins that bind onto cell surface receptors, triggering a series of signals that regulate the bodys ability to grow, renew and heal. Due to the regenerative properties of growth factors, they have been exploited for bone healing in orthopedic applications. Since September 1, 2015, there are two main growth factor products offered in the U.S. market: INFUSE® by Medtronic and AUGMENT® by Wright Medical. Strykers OP-1 which had been sold to Olympus Biotech is no longer available as Olympus Biotech ceased sales May 31, 2014. Strykers OP-1 is a different form of bone morphogenic proteins (BMPs) that belong to a larger family of proteins called transforming growth factors.
Each of the three markets discussed in the report has a unique set of factors affecting its growth profile. In terms of the market drivers, for example, the bone graft market is seeing increasing adoption rate as newly trained surgeons are entering the workforce. The viscosupplementation market continues to bring improved products along with expanded indications. The bone stimulator market maintains a high clinical success rate and is therefore also increasing its adoption rate.
The very first bone stimulator device in Canada received Health Canada license in November 1999. As of 2015 there were a total of seven players in the long bone growth stimulator market, three of which also had either a separate device for spinal application or had their only device also indicated for spine. For the purpose of this report, estimated units were separated by indication and only long bone (i.e. fractures) related units were included. There is a brief discussion regarding the break-down between long bone and spinal units in the Electrical Stimulator Market section and under the competitive analysis section. For context, the long bone market is estimated to be more than seven times bigger than spine ($8.0 vs. $1.1 million, respectively) as of 2015. There is also a brief discussion on the estimated break-down between units sold and units rented under the Ultrasonic Stimulator Market section and under the competitive analysis section.